Stewart Niefield, MD
Internal Medicine · Houston, TXNPI 1255336871
Payments from drug & device makers
Across 259 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$597
- Astellas Pharma US Inc$490
- Amarin Pharma, Inc.$369
- Lilly USA, LLC$296
- Inspire Medical Systems, Inc.$271
- Merck$270
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,457100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $597 |
| Astellas Pharma US Inc | 24 | $490 |
| Amarin Pharma, Inc. | 24 | $369 |
| Lilly USA, LLC | 16 | $296 |
| Inspire Medical Systems, Inc. | 7 | $271 |
| Merck | 23 | $270 |
| AbbVie(2 entities) | 14 | $206 |
| Abbott | 7 | $199 |
| Johnson & Johnson | 14 | $195 |
| Boehringer Ingelheim | 11 | $188 |
| Vanda Pharmaceuticals Inc. | 6 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $127 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $117 |
| Gilead | 8 | $115 |
| GSK | 6 | $105 |
| Exact Sciences | 5 | $87 |
| Amgen | 5 | $81 |
| Sanofi-aventis U.S. LLC | 6 | $79 |
| AstraZeneca | 6 | $78 |
| Pfizer | 4 | $78 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Novartis | 2 | $34 |
| Titan Spine, LLC | 1 | $24 |
| Napo Pharmaceuticals Inc | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Metuchen Pharmaceuticals | 1 | $20 |
| EMD Serono, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Assertio Therapeutics, Inc. | 1 | $19 |
| Cardiovascular Systems Inc. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Alk-abello, Inc | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$131
How this compares
$4,457 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 17 | $36,420 |
| JardianceEmpagliflozin | 17 | $30,933 |
| OzempicSemaglutide | 15 | $25,193 |
| EliquisApixaban | 23 | $22,002 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $13,906 |
| XareltoRivaroxaban | 17 | $13,778 |
| SynthroidLevothyroxine Sodium | 42 | $4,530 |
| LantusInsulin Glargine,hum.Rec.Anlog | 12 | $3,037 |
| Atorvastatin Calcium | 253 | $2,424 |
| Novolog FlexpenInsulin Aspart | 15 | $2,023 |
| Losartan Potassium | 149 | $1,642 |
| Levothyroxine Sodium | 128 | $1,493 |
| Rosuvastatin Calcium | 88 | $965 |
| Escitalopram Oxalate | 48 | $902 |
| Simvastatin | 78 | $876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $296 | $36,42017 claims |
| Boehringer IngelheimJardiance | $188 | $30,93317 claims |
| Novo NordiskOzempic | $597 | $25,19315 claims |
| PfizerEliquis | $78 | $22,00223 claims |
| Johnson & JohnsonXarelto | $195 | $13,77817 claims |
| AbbVieSynthroid | $206 | $4,53042 claims |
| Sanofi-aventis U.S. LLCLantus | $79 | $3,03712 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $11 | $1,493128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.